PRTA
Prothena Corporation plc
NASDAQ · IEHealthcareBiotechnology
$8.67+0.12%
Price as of Jul 20, 2026
PRTA profitability
Prothena Corporation plc profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 46.8%
- EBITDA margin
- -129.0%
- EBIT margin
- -217.9%
- Net margin
- -260.9%
- Free cash flow margin
- -140.6%
Returns
- Return on equity
- -48.4%
- Return on assets
- -43.2%
- Return on invested capital
- -39.4%
- Asset turnover
- 0.17x
Cash efficiency
- Cash from operations
- -$81.3M
- Cash per share
- $6.29
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.